Product image of Jadiza (Ethinylestradiol, Levonorgestrel | Lactose Monohydrate) supplied by GNH India

Jadiza

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose Monohydrate
Origin:
EU

Jadiza (Ethinylestradiol, Levonorgestrel | Lactose Monohydrate)

Ethinylestradiol and Levonorgestrel, the active ingredients in Jadiza, are combined estrogen‑progestogen oral contraceptives presented as oral tablets for oral use. They work together to prevent pregnancy in women of reproductive age and comply with EU regulatory standards, requiring a prescription from a qualified health professional.

GNH India supplies Jadiza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable global distribution and supporting customers with technical and regulatory assistance, and ensuring compliance with local import regulations.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Jadiza, a combined estrogen‑progestogen oral contraceptive, is used to regulate hormonal pathways that prevent pregnancy.
  • Contraception: prevents pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the endometrium.
  • Family planning: provides a reliable, reversible method of birth control for women of reproductive age.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual‑related discomfort.
  • Hormonal balance: stabilizes estrogen and progesterone levels during the menstrual cycle.

How It Works

  • Ethinylestradiol binds to estrogen receptors while levonorgestrel binds to progesterone receptors, together suppressing the hypothalamic‑pituitary‑gonadal axis. This inhibition reduces the secretion of luteinizing hormone and follicle‑stimulating hormone, preventing follicular development and ovulation. The progestogenic component also increases the viscosity of cervical mucus and induces endometrial changes that are unfavorable for implantation. Additionally, the estrogen component stabilizes the endometrial lining, contributing to cycle control.

Side Effects

Jadiza may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

  • Nausea
  • Headache
  • Breast tenderness
  • Spotting between periods

Serious or Rare Side Effects

  • Deep vein thrombosis
  • Pulmonary embolism
  • Severe allergic reaction (anaphylaxis)

Precautions & Warnings

  • When prescribing Jadiza, healthcare professionals should consider several safety precautions.
  • Pregnancy avoidance: product is contraindicated in pregnancy (Category X).
  • Smoking: avoid use in women over 35 who smoke due to increased thrombotic risk.
  • Cardiovascular risk: assess history of thromboembolic disorders before initiating therapy.
  • Liver disease: use with caution in patients with hepatic impairment.
  • Drug review: evaluate concomitant medications that may reduce contraceptive effectiveness.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Jadiza can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) may markedly reduce contraceptive effectiveness.
  • Concurrent use with other estrogen‑containing products increases risk of estrogen‑related adverse events.

Moderate Interactions (Monitor Closely)

  • Antifungal agents such as ketoconazole can increase plasma levels of levonorgestrel, requiring monitoring for side effects.
  • St. John’s wort may lower effectiveness of hormonal contraception; consider alternative birth control.
  • Anticoagulants may increase the risk of thrombotic events when combined with hormonal contraceptives; monitor clotting parameters.

Frequently Asked Questions

Jadiza is a combined estrogen‑progestogen oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It is prescribed as a reversible, hormone‑based method of birth control and may also help regulate menstrual bleeding patterns.

Ethinylestradiol and levonorgestrel act together to suppress the hypothalamic‑pituitary‑ovarian axis, lowering luteinizing hormone and follicle‑stimulating hormone release. This prevents ovulation, thickens cervical mucus, and creates endometrial changes that are hostile to implantation, thereby averting pregnancy.

The specific dosing regimen for Jadiza is determined by the prescribing clinician based on the product’s labeling and the patient’s individual health profile. Healthcare providers select the appropriate tablet strength, schedule, and duration in accordance with approved prescribing information.

Jadiza is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can harm the fetus. Use while breastfeeding is generally not recommended without medical guidance, as hormonal exposure may affect milk production and infant health.

To order Jadiza, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Jadiza contains the standard dose combination of ethinyloestradiol and levonorgestrel, a widely used regimen in combined oral contraceptives. Its efficacy and safety profile are comparable to other products with the same active ingredients, while formulation differences such as tablet size or excipients may vary between brands.

Jadiza tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and ensure they are out of reach of children.

Jadiza is taken orally, usually once daily at the same time each day, following the schedule indicated on the prescription label. Patients should swallow the tablet whole with water and not skip doses to maintain contraceptive effectiveness.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, and stroke, especially in women with pre‑existing risk factors. Rare but severe allergic reactions (anaphylaxis) and hepatic adenomas have also been reported. Prompt medical attention is required if any of these occur.

Jadiza should not be used by women who are pregnant, have a known hypersensitivity to any component, have a history of thromboembolic disorders, uncontrolled hypertension, certain liver diseases, or who smoke and are over 35 years of age. A thorough medical assessment is essential before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT